Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

N-(Phosphonacetyl)-L-aspartate (PALA): current status

M Rozencweig, R Abele, M Piccart

    Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
    |January 1, 1980
    PubMed
    Summary

    N-(Phosphonoacetyl)-L-aspartate (PALA) shows promise as an oncolytic agent against solid tumors. Its clinical use is limited by reversible mucocutaneous toxicity, with ongoing trials to determine its full potential in human cancer treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
    Same author

    Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

    Cancer chemotherapy and pharmacology·2014
    Same author

    Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

    European journal of cancer (Oxford, England : 1990)·2012

    Area of Science:

    • Oncology
    • Pharmacology
    • Biochemistry

    Background:

    • N-(Phosphonoacetyl)-L-aspartate (PALA) is a synthetic antimetabolite.
    • PALA demonstrates significant oncolytic properties in experimental solid tumor models.

    Purpose of the Study:

    • To evaluate the single-agent activity of PALA in human cancer.
    • To understand the dose-limiting toxicities of PALA in clinical settings.

    Main Methods:

    • Clinical trials were initiated to assess PALA's efficacy.
    • Toxicity profiles, specifically mucocutaneous effects, were monitored.

    Main Results:

    • PALA exhibits oncolytic activity against diverse experimental solid tumors.
    • Mucocutaneous toxicity is identified as the dose-limiting factor in clinical use.

    Related Experiment Videos

  • This toxicity is reversible and directly related to the administered dose.

    • Conclusions:

    • PALA possesses notable antineoplastic potential.
    • Further clinical data is required to fully delineate its single-agent activity and therapeutic window in human cancers.